SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $46.99 to $46.99
• 50-Day Range: $46.46 to $46.99
• 52-Week Range: $28.21 to $62.00
• Volume: N/A
• Average Volume: 2.66 million shs
• Market Capitalization: $3.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Hold

SWTX Stock Analysis - Frequently Asked Questions

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics (NASDAQ:SWTX) issued its quarterly earnings results on Friday, May, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.30. The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative trailing twelve-month return on equity of 51.10% and a negative net margin of 115.60%.

Does SpringWorks Therapeutics have any subsidiaries?

SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 10/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SWTX
• CIK: 1773427
• Web: www.springworkstx.com
• Phone: 203-883-9490
• Fax: N/A
• Employees: 230
• Year Founded: 2017

Price Target and Rating

• Average Price Target for SpringWorks Therapeutics: $50.00
• High Price Target: $65.00
• Low Price Target: $47.00
• Potential Upside/Downside: +6.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$258.13 million
• Net Margins: -115.60%
• Pretax Margin: -115.60%
• Return on Equity: -51.10%
• Return on Assets: -43.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.33
• Quick Ratio: 4.18

Sales & Book Value

• Annual Sales: $191.59 million
• Price / Sales: 18.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.47 per share
• Price / Book: 7.26

Miscellaneous

• Outstanding Shares: 75,350,000
• Free Float: 69,449,000
• Market Cap: $3.54 billion
• Optionable: Optionable
• Beta: 0.68